Narcolepsy type 1 (NT1) is one of two primary classifications of narcolepsy. Its defining feature, beyond the hallmark excessive daytime sleepiness (EDS) shared by both types, is cataplexy — a brief, sudden loss of muscle tone that occurs exclusively in NT1. Managing both EDS and cataplexy simultaneously is the central therapeutic objective in this population.
Only patients with narcolepsy type 1 experience cataplexy alongside excessive daytime sleepiness. This combination distinguishes NT1 from NT2 and shapes the treatment selection: an approach effective for EDS alone is insufficient — the chosen strategy must address cataplexy as well.
First-line management of NT1 with cataplexy and EDS centres on a monotherapy approach using a specific agent recognised as efficacious for both symptoms — the complete regimen, agent selection, and titration pathway are detailed in the full protocol.
DOI: 10.9740/mhc.2025.12.258
There are 2 primary classifications of narcolepsy, narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2).
The hallmark symptom is excessive daytime sleepiness (EDS), but only patients with NT1 experience cataplexy.
Cataplexy is a brief, sudden loss of muscle tone.
The patient in this case was started on SXB to allow for monotherapy to treat both EDS and cataplexy.
Based on clinical experience, it is efficacious in managing the symptoms of NT1 and considered a first-line agent.
Cataplexy effects occur soon after initiation, but WPA onset may take weeks to be evident.
Screening typically begins in a clinic with the administration of the Epworth Sleepiness Scale (ESS) on which scores greater than 10 indicate the need for additional evaluation.
View source ↗